Geron Corporation
NASDAQ•GERN
CEO: Dr. John A. Scarlett M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1996-07-31
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Contact Information
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States
650-473-7700
Market Cap
$919.23M
P/E (TTM)
-11.2
19.9
Dividend Yield
--
52W High
$2.01
52W Low
$1.04
52W Range
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$48.02M+0.00%
4-Quarter Trend
EPS
-$0.05+0.00%
4-Quarter Trend
FCF
-$22.10M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
RYTELO Product Revenue Surge Net product revenue reached $183.6M in 2025, showing 58% growth over 2024 sales figures.
Total Revenue Skyrockets Total revenues hit $183.9M in 2025, a 139% increase compared to the prior year's $77.0M.
Cash Position Strong Ended 2025 with $401.1M in cash, cash equivalents, and marketable securities for operations.
Risk Factors
Commercialization Success Dependent Near-term prospects entirely rely on successful U.S. commercialization of RYTELO for lower-risk MDS.
Workforce Reduction Implemented Strategic restructuring announced in December 2025 resulting in workforce reduction of approximately one-third.
Facing Securities Litigation Company and officers named in multiple securities class action and derivative lawsuits; defense costs are substantial.
Outlook
EU Commercialization Planned Preparing for planned RYTELO commercialization launch in select European Union markets throughout 2026.
IMpactMF Trial Analysis Timing Expect interim overall survival analysis for the IMpactMF Phase 3 trial in the second half of 2026.
Operating Expenses Expected Down Expect SG&A expenses to decrease in 2026 due to headcount reduction savings from restructuring efforts.
Peer Comparison
Revenue (TTM)
$262.60M
$198.55M
$183.88M
Gross Margin (Latest Quarter)
672.1%
124.4%
97.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TYRA | $1.76B | -16.4 | -41.2% | 2.1% |
| VIR | $1.24B | -2.8 | -49.3% | 18.6% |
| SVRA | $1.14B | -10.4 | -86.6% | 21.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data